Insulin-like growth factors and cancer: No role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies

British Journal of Cancer

Volumn 95, Issue 1, 2006, Pages 112-117

  Morris, J K ^a   George, L M ^a   Wu, T ^a   Wald, N J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cancer screening; Cohort studies; Epidemiology; Insulin like growth factors; Meta analysis

Indexed keywords

SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ARTICLE; CANCER SCREENING; CASE CONTROL STUDY; CLINICAL STUDY; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SERUM; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; UNITED KINGDOM;

ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; COLORECTAL NEOPLASMS; GREAT BRITAIN; HUMANS; LUNG NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SOMATOMEDINS;

EID: 33745535924     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603200     Document Type: Article

References (24)

1. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak MN (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566
2. Chen C, Lewis SK, Voigt L, Fitzpatrick A, Plymate SR, Weiss NS (2005) Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor 1, insulin-like growth factor binding protein 3, and insulin. Cancer 103: 76-84
3. Giovannucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, Majeed N, Colditz GA, Speizer FE, Hankinson SE (2000) A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 9: 345-349
4. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB (2000) Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IFG-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 85: 4258-4265
5. Hunt KJ, Toniolo P, Akhmedkhanov A, Lukanova A, Dechaud H, Rinaldi S, Zeleniuch-Jacquotte A, Shore RE, Riboli E, Kaaks R (2002) Insulin-like growth factor 2 and colorectal cancer risk in women. Cancer Epidemiol Biomarkers Prev 11: 901-905
6. Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H, Rinaldi S, Zeleniuch-Jacquotte A, Shore RE, Riboli E (2000) Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 92: 1592-1600
7. Lacey JV, Hsing AW, Fillmore CM, Hoffman S, Helzlsouer KJ, Comstock GW (2001) Null association between insulin-like growth factors, insulin-like growth factor-binding proteins, and prostate cancer in a prospective study. Cancer Epidemiol Biomarkers Prev 10: 1101-1102
8. London SJ, Yuan J-M, Travlos GS, Gao Y-T, Wilson RE, Ross RK, Yu MC (2002) Insulin-like growth factor I, IGF-bindin protein 3, and lung cancer risk in a prospective study of men in China. J Natl Cancer Inst 94: 749-754
9. Lukanova A, Toniolo P, Akhmedkhanov A, Biessy C, Haley NJ, Shore RE, Riboli E, Rinaldi S, Kaaks R (2001) A prospective study of insulin-like growth factor-I, IFG-binding proteins-1, -2 and -3 and lung cancer risk in women. Int J Cancer 92: 888-892
10. Lukanova A, Lundin E, Toniolo P, Micheli A, Akhemkhanov A, Rinaldi S, Muti P, Lenner P, Krogh V, Biessy C, Zeleniuch-Jacquotte A, Berrino F, Hallmans G, Riboli E, Kaaks R (2002) Circulating levels of insulin-like growth factor-1 and risk of ovarian cancer. Int J Cancer 101: 549-554
11. Lukanova A, Zeleniuch-Jacquotte A, Lundin E, Micheli A, Arslan AA, Rinaldi S, Muti P, Lenner P, Koenig KL, Bessy G, Krogh V, Riboli E, Shore RE, Stattin P, Berrino F, Hallmans G, Toniolo P, Kaaks R (2004) Prediagnostic levels of C-Peptide, IGF-1, IGFBP -1,-2 and -3 and risk of endometrial cancer. Int J Cancer 108: 262-268
12. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I AND IFG-binding protein-3. J Natl Cancer Inst 91: 620-625
13. Meyer F, Galan P, Douville P, Bairati I, Kegle P, Bertrais S, Czernichow S, Hercberg S (2005) A prospective study of the insulin-like growth factor axis in relation with prostate cancer in the SU.VI.MAX trial. Cancer Epidemiol Biomarkers Prev 14: 2269-2272
14. Nomura AMY, Stemmermann GN, Lee J, Pollak MN (2003) Serum insulin-like growth factor 1 and subsequent risk of colorectal cancer among Japanese-American men. Am J Epidemiol 158: 424-431
15. Palmqvist R, Hallmans G, Rinaldi S, Biessy C, Stenling R, Riboli E, Kaaks R (2002) Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut 50: 642-646
16. Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E (2005) Plasma inculin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 16: 255-262
17. Probst-Hensch NM, Yuan J-M, Stanczyk FZ, Gao Y-T, Ross RK, Yu MC (2001) IGF-1, IFG-2 and IGF-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer 85: 1695-1699
18. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IFG binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363: 1346-1353
19. Spitz MR, Barnett MJ, Goodman GE, Thornquist MD, Wu X, Pollak M (2002) Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the β-carotene and retinol efficacy trial cohort. Cancer Epidemiol Biomarkers Prev 11: 1413-1418
20. Stattin P, Rinaldi S, Biessy C, Stenman U-H, Hallmans G, Kaaks R (2004) High levels of circulating insulin-like growth factor-1 increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 22: 3104-3112
21. Wakai K, Ito Y, Suzuki K, Tamakoshi A, Seki N, Ando M, Ozasa K, Watanabe Y, Kondo T, Nishino Y, Ohno Y (2002) Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death: a case-control study nested in the Japan Collaborative Cohort (JACC) Study. Jpn J Cancer Res 93: 1279-1286
22. Wald NJ, Hackshaw AK, Frost CD (1999) When can a risk factor be used as a worthwhile screening test? BMJ 319: 1562-1565
23. Wald NJ, Morris JK, Rish S (2005) The efficacy of combining several risk factors as a screening test. J Med Screen 12: 197-201
24. Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D (2003) Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 63: 3991-3994